Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F15%3A10316248" target="_blank" >RIV/00216208:11130/15:10316248 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064203:_____/15:10316248
Výsledek na webu
<a href="http://dx.doi.org/10.1056/NEJMoa1510665" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1510665</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1510665" target="_blank" >10.1056/NEJMoa1510665</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Popis výsledku v původním jazyce
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one ortwo regimens of antiangiogenic therapy were randomly assigned (in a 1: 1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1)
Název v anglickém jazyce
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Popis výsledku anglicky
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one ortwo regimens of antiangiogenic therapy were randomly assigned (in a 1: 1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1)
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Svazek periodika
373
Číslo periodika v rámci svazku
19
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
11
Strana od-do
1803-1813
Kód UT WoS článku
000364144000004
EID výsledku v databázi Scopus
2-s2.0-84946607195